Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer

被引：5

作者：

Aisa, Adilai ^{[1
,2
]}

Weng, Shanshan ^{[1
,2
]}

Li, Xinyu ^{[1
,2
]}

Zhang, Ding ^{[1
,2
]}

Yuan, Ying ^{[1
,2
,3
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 2, Minist Educ,Sch Med, Key Lab Canc Prevent & Intervent,Dept Med Oncol, Hangzhou 310009, Zhejiang, Peoples R China

[2] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China

[3] 88 Jiefang Rd, Hangzhou 310009, Peoples R China

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 180卷

基金：

中国国家自然科学基金;

关键词：

HER-2; Immunotherapy; Immune checkpoint inhibitors; HER-2 targeted treatments; Gastroesophageal cancer; TUMOR-INFILTRATING LYMPHOCYTES; ANTIBODY-DRUG CONJUGATE; DEATH LIGAND 1; BREAST-CANCER; GASTRIC-CANCER; SINGLE-ARM; OPEN-LABEL; IN-VITRO; IMMUNOTHERAPY; TRASTUZUMAB;

D O I：

10.1016/j.critrevonc.2022.103864

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

GEC is one of the most common cancers and has become a significant health burden worldwide. HER-2 is a protooncogene, amplified or overexpressed in different tumors, and associated with a worse prognosis. Trastuzumab plus chemotherapy is the current standard treatment for advanced HER-2 positive GEC. However, it still does not benefit well all patients. HER-2 targeted therapy can up-regulate the expression of PD-1, CTL-4, and TAMs in the tumor microenvironment, strengthen the ADCC process, and enhance the efficacy of immunotherapy. While immune checkpoint inhibitors could reduce drug resistance to anti-HER-2 drugs. Moreover, immunotherapy combined with HER-2 targeted therapy in HER-2 positive GEC has shown perceptible efficacy and acceptable side effects in clinical trials and is regarded as a new therapeutic strategy for GEC. However, there remain significant challenges and requires more research to improve the survival benefit of this therapeutic approach.

引用

页数：10

共 92 条

[1] Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade [J].

Abida, Wassim ;

Cheng, Michael L. ;

Armenia, Joshua ;

Middha, Sumit ;

Autio, Karen A. ;

Vargas, Hebert Alberto ;

Rathkopf, Dana ;

Morris, Michael J. ;

Danila, Daniel C. ;

Slovin, Susan F. ;

Carbone, Emily ;

Barnett, Ethan S. ;

Hullings, Melanie ;

Hechtman, Jaclyn F. ;

Zehir, Ahmet ;

Shia, Jinru ;

Jonsson, Philip ;

Stadler, Zsofia K. ;

Srinivasan, Preethi ;

Laudone, Vincent P. ;

Reuter, Victor ;

Wolchok, Jedd D. ;

Socci, Nicholas D. ;

Taylor, Barry S. ;

Berger, Michael F. ;

Kantoff, Philip W. ;

Sawyers, Charles L. ;

Schultz, Nikolaus ;

Solit, David B. ;

Gopalan, Anuradha ;

Scher, Howard I. .

JAMA ONCOLOGY, 2019, 5 (04) :471-478

[2] Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer [J].

Ahn, Daniel ;

Walden, Daniel ;

Bekaii-Saab, Tanios .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (05) :437-441

[3] Challenges of evaluating immunotherapy efficacy in solid tumors [J].

Bai, Rilan ;

Li, Wenqian ;

Du, Nawen ;

Cui, Jiuwei .

CHINESE JOURNAL OF CANCER RESEARCH, 2019, 31 (06) :853-861

[4] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Feyereislova, Andrea ;

Chung, Hyun C. ;

Shen, Lin ;

Sawaki, Akira ;

Lordick, Florian ;

Ohtsu, Atsushi ;

Omuro, Yasushi ;

Satoh, Taroh ;

Aprile, Giuseppe ;

Kulikov, Evgeny ;

Hill, Julie ;

Lehle, Michaela ;

Ruschoff, Josef ;

Kang, Yoon-Koo .

LANCET, 2010, 376 (9742) :687-697

[5]

Bartley AN, 2016, AM J CLIN PATHOL, V146, P647, DOI [10.1093/AJCP/AQW206, 10.1093/ajcp/aqw206]

[6]

Booth ME, 2022, BIODRUGS, V36, P473, DOI 10.1007/s40259-022-00527-9

[7] Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia [J].

Cao, Y. ;

Qin, S. ;

Luo, S. ;

Li, Z. ;

Cheng, Y. ;

Fan, Y. ;

Sun, Y. ;

Yin, X. ;

Yuan, X. ;

Li, W. ;

Liu, T. ;

Hsu, C-H ;

Lin, X. ;

Kim, S-B ;

Kojima, T. ;

Zhang, J. ;

Lee, S-H ;

Bai, Y. ;

Muro, K. ;

Doi, T. ;

Bai, C. ;

Gu, K. ;

Pan, H-M ;

Bai, L. ;

Yang, J-W ;

Cui, Y. ;

Lu, W. ;

Chen, J. .

ESMO OPEN, 2022, 7 (01)

[8] ZW25 Effective in HER2-Positive Cancers [J].

Caruso, Catherine .

CANCER DISCOVERY, 2019, 9 (01) :8-8

[9] MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma [J].

Catenacci, Daniel V. T. ;

Rosales, Minori ;

Chung, Hyun Cheol ;

Yoon, Harry H. ;

Shen, Lin ;

Moehler, Markus ;

Kang, Yoon-Koo .

FUTURE ONCOLOGY, 2021, 17 (10) :1155-1164

[10] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial [J].

Catenacci, Daniel V. T. ;

Kang, Yoon-Koo ;

Park, Haeseong ;

Uronis, Hope E. ;

Lee, Keun-Wook ;

Ng, Matthew C. H. ;

Enzinger, Peter C. ;

Park, Se Hoon ;

Gold, Philip J. ;

Lacy, Jill ;

Hochster, Howard S. ;

Oh, Sang Cheul ;

Kim, Yeul Hong ;

Marrone, Kristen A. ;

Kelly, Ronan J. ;

Juergens, Rosalyn A. ;

Kim, Jong Gwang ;

Bendell, Johanna C. ;

Alcindor, Thierry ;

Sym, Sun Jin ;

Song, Eun-Kee ;

Chee, Cheng Ean ;

Chao, Yee ;

Kim, Sunnie ;

Lockhart, A. Craig ;

Knutson, Keith L. ;

Yen, Jennifer ;

Franovic, Aleksandra ;

Nordstrom, Jeffrey L. ;

Li, Daner ;

Wigginton, Jon ;

Davidson-Moncada, Jan K. ;

Rosales, Minori Koshiji ;

Bang, Yung-Jue .

LANCET ONCOLOGY, 2020, 21 (08) :1066-1076

← 1 2 3 4 5 6 7 8 9 10 →